218 recruiting. 218 Phase 2, 67 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 218 | Recruiting 218 |
| Phase 1 | 67 | Recruiting 67 |
| Phase 3 | 5 | Recruiting 5 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-11-11 | 2026-11-06 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| A Study of Ropeg-Interferon in People With Polycythemia Vera Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2026-10-30 | 2026-11-03 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-29 | 2026-11-05 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-28 |
| A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes Dibotatug (DR-01) - Bone Marrow Failure Syndromes, Aplastic Anemias | Phase 1 / Phase 2 | Recruiting | Dren Bio | 60 | 2026-08-14 | 2026-11-04 |
| Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT RTC conditioning regimen and Modified Bu/Cy conditioning regimen - Myelodysplastic Syndromes | Phase 2 | Recruiting | Peking University People's Hospital | 120 | 2026-07-15 | 2026-09-16 |
| A Study of Rusfertide in Japanese Adults With Polycythemia Vera Rusfertide - Polycythemia Vera | Phase 2 | Recruiting | Takeda | 9 | 2026-07-14 | 2026-10-02 |
| Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Ropeginterferon alfa-2b (P1101) - Chronic Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-13 | 2026-10-13 |
| Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia Isatuximab - Aplastic Anemia | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-30 | 2026-09-21 |
| A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis TQ05105 Tablets (Rovadicitinib Tablets) - Myelofibrosis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 51 | 2026-06-18 | 2026-07-15 |
| Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS Ivosidenib - AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Ruijin Hospital | 20 | 2026-05-22 | 2026-05-26 |
| Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial) Nicotinamide Riboside, Pterostilbene - Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome | Phase 2 | Recruiting | University of Colorado, Denver | 10 | 2026-05-20 | 2026-06-03 |
| Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Asciminib single agent - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-04-28 | 2026-10-15 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes TAK-226 - Myelodysplastic Syndromes | Phase 2 | Recruiting | Takeda | 42 | 2026-04-22 | 2026-10-28 |
| Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia Pacritinib - Myelofibrosis，MF | Phase 2 | Recruiting | Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | 30 | 2026-04-15 | 2026-10-02 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
Showing 20 of 218. Sign in to see all of them.
Myelodysplastic Syndromes (106) · Leukemia, Myeloid, Acute (79) · Leukemia, Myelomonocytic, Chronic (34) · Primary Myelofibrosis (33) · Myeloproliferative Disorders (31) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (31) · Anemia, Refractory, with Excess of Blasts (26) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (26) · Anemia, Aplastic (25) · Leukemia, Biphenotypic, Acute (17) · Lymphoma, Non-Hodgkin (16) · Hodgkin Disease (14) · Polycythemia Vera (12) · Leukemia (11) · Hematologic Neoplasms (10)
Hemic and Lymphatic Diseases (218) · Hematologic Diseases (214) · Neoplasms (128) · Neoplasms by Histologic Type (117) · Leukemia, Myeloid (105) · Leukemia (103) · Pathological Conditions, Signs and Symptoms (74) · Pathologic Processes (71) · Disease Attributes (68) · Chronic Disease (63) · Anemia (60) · Myeloproliferative Disorders (57) · Immune System Diseases (52) · Lymphoproliferative Disorders (47)
fludarabine (33) · Cyclophosphamide (31) · Azacitidine (21) · Whole-Body Irradiation (20) · venetoclax (20) · Specimen Handling (18) · Tacrolimus (18) · fludarabine phosphate (18) · ruxolitinib (18) · Mycophenolic Acid (16) · Cytarabine (15) · Biopsy (14) · Busulfan (14) · Melphalan (13) · Stem Cell Transplantation (11)
M.D. Anderson Cancer Center (26) · Fred Hutchinson Cancer Center (9) · National Cancer Institute (NCI) (7) · Masonic Cancer Center, University of Minnesota (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · Memorial Sloan Kettering Cancer Center (5) · City of Hope Medical Center (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · St. Petersburg State Pavlov Medical University (4) · Takeda (4) · Mayo Clinic (3) · Novartis Pharmaceuticals (3) · Peking University People's Hospital (3) · Washington University School of Medicine (3) · Assistance Publique - Hôpitaux de Paris (2)
United States (136) · China (35) · France (27) · Spain (22) · United Kingdom (21) · Germany (20) · Italy (20) · Canada (18) · Australia (14) · South Korea (12) · Japan (8) · Netherlands (8) · Poland (7) · Belgium (6) · Russia (6)
Richard W Childs, M.D. (3) · Anand A Patel (2) · Andromachi Scaradavou, MD (2) · Bhavisha A Patel, M.D. (2) · Courtney DiNardo (2) · Courtney DiNardo, MD (2) · Elias Jabbour, MD (2) · Fadi Haddad, MD (2) · Harinder Gill, MD (2) · Jordan Milner, MD (2) · Paul Szabolcs, MD (2) · Raajit Rampal, MD, PhD (2)
PMID 19117511, PMID 22517900, PMID 22796534, PMID 24319166, PMID 24319167, PMID 24842530, PMID 25797174, PMID 26359881, PMID 2889870, PMID 29702001, PMID 30115541, PMID 30335787, PMID 32556286, PMID 32634238, PMID 32750127, PMID 32813873, PMID 33159275, PMID 34329576, PMID 34889407, PMID 35078972, PMID 35854224, PMID 35973199, PMID 36251488, PMID 36402146, PMID 36902217, PMID 37130682, PMID 37595058, PMID 38277619, PMID 39028925, PMID 39316768, PMID 39352751, PMID 39392121, PMID 39537648, PMID 39665627, PMID 39773995, PMID 40073835, PMID 40193193, PMID 40369607, PMID 40500616, PMID 40513054, PMID 40696207, PMID 40859225, PMID 41056522, PMID 41144785, PMID 41175032, PMID 41753113, PMID 42013378, PMID 42200455
2023 (7), P30CA033572 (4), 2025 (3), P01CA078902 (2), P30CA015704 (2), P30CA016672 (2), U10CA180888 (2), 2017 (1), 2018 (1), P01CA018029 (1), P01CA108671 (1), P30CA014089 (1), P50CA097274 (1), R01CA211044 (1), R01CA254955 (1)